Page 6 - லாரஸ் ஆய்வகங்கள் லிமிடெட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Excellent stock, excellent results and excellent appreciation Thomson Reuters scale LL is given as

Excellent stock, excellent results and excellent appreciation Thomson Reuters scale LL is given as
moneycontrol.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from moneycontrol.com Daily Mail and Mail on Sunday newspapers.

Thomson reutersLaurus labs ltdLaurus labsதாம்சன் ராய்ட்டர்ஸ்லாரஸ் ஆய்வகங்கள் லிமிடெட்லாரஸ் ஆய்வகங்கள்

Laurus Labs Q3 net profit zooms to ₹273 cr - The Hindu BusinessLine

Laurus Labs Q3 net profit zooms to ₹273 cr January 28, 2021 × Laurus Labs Ltd posted a record increase in net profit at ₹273 crore in the third quarter ended December 2020 compared to ₹73 crore in the same period in the previous fiscal. The company’s revenue grew by 76 per cent at ₹1,288 crore as against ₹730 crore in the year-ago period. “Our Consolidated revenue for the quarter increased by 76 pc driven by growth in all the divisions. we have been able to sustain our EBITDA margins, and our profitability has also improved to ₹273 crs for the quarter , Satyanarayana Chava, Founder & CEO, Laurus Labs said in a release on Thursday.

Satyanarayana chavaLaurus bioLaurus labs ltdLaurus labsசத்தியநாராயணா சாவாலாரஸ் உயிர்லாரஸ் ஆய்வகங்கள் லிமிடெட்லாரஸ் ஆய்வகங்கள்

Laurus Labs Ltd Board approves 2nd interim dividend of Rs 0 40 for FY21

Laurus Labs Ltd Board approves 2nd interim dividend of Rs. 0.40 for FY21 Posted On: 2021-01-28 03:24:57 (Time Zone: Arizona, USA) The Board of Directors of Laurus Labs Ltd in their meeting held on January 28, 2021 have approved for the payment of 2nd interim dividend of 40 Paise (20%) per equity share of Rs.2/- each, for the Financial Year 2020-21. The Company has fixed February 09, 2021 as Record Date for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after February 18, 2021. Shares of Laurus Labs Ltd was last trading in BSE at Rs.366.2 as compared to the previous close of Rs. 379.35. The total number of shares traded during the day was 124124 in over 3390 trades.

United statesLaurus labs ltd boardBoard of directors laurus labs ltdLaurus labs ltdLabs ltd boardTime zoneFinancial yearஒன்றுபட்டது மாநிலங்களில்லாரஸ் ஆய்வகங்கள் லிமிடெட் பலகைபலகை ஆஃப் இயக்குநர்கள் லாரஸ் ஆய்வகங்கள் லிமிடெட்லாரஸ் ஆய்வகங்கள் லிமிடெட்ஆய்வகங்கள் லிமிடெட் பலகைநேரம் ஸோந்நிதி ஆண்டு

Global Hydroxychloroquine Market Present Scenario, Key Vendors, Industry Share, and Growth Forecast up to 2027 – KSU

The Global Hydroxychloroquine Market research report released by Data Bridge Market research provides the market segmentation based on type, market size, Product launches and applications. It identifies the global adoption of the products as one of the growth factors, driven by the availability of the product. The global research report gives the brief summary of the leading players operating in the market, their product offering, key developments, investments feasibility and returns. This Global Hydroxychloroquine Market report which is outcome of the ultimate dedication of industry experts, has an abundance of data that can profit anybody, regardless of their business or academic interest.

United statesHong kongUnited kingdomSouth koreaRepublic ofSouth africaSaudi arabiaAdvanz pharmaZydus cadilaLaurus labs ltdSun pharmaceutical industries ltdAppco pharmaAmneal pharmaceuticals incTeva pharmaceutical industries ltdMarket researchIntas pharmaceuticals ltd

Laurus Labs Ltd posts consolidated PAT of Rs 272 85 crores in Q3 FY2020-21

Laurus Labs Ltd posts consolidated PAT of Rs. 272.85 crores in Q3 FY2020-21 Posted On: Laurus Labs Ltd has reported financial results for the period ended December 31, 2020. Financial Results (Q3 FY20-21) - QoQ Comparison The company has reported total income of Rs.1295.35 crores during the period ended December 31, 2020 as compared to Rs.1143.96 crores during the period ended September 30, 2020. The company has posted net profit / (loss) of Rs.272.85 crores for the period ended December 31, 2020 as against net profit / (loss) of Rs.242.27 crores for the period ended September 30, 2020. The company has reported EPS of Rs.5.07 for the period ended December 31, 2020 as compared to Rs.4.50 for the period ended September 30, 2020.

United statesVv ravi kumarSatyanarayana chavaRichcore lifesciencesLaurus bioLaurus labs ltdLabs ltdTime zoneFinancial officerTotal revenueஒன்றுபட்டது மாநிலங்களில்வி வி ரவி குமார்சத்தியநாராயணா சாவாலாரஸ் உயிர்லாரஸ் ஆய்வகங்கள் லிமிடெட்ஆய்வகங்கள் லிமிடெட்